Please find all related articles below.
This article gives a brief overview of health related developments, activities and events in the EU’s economic governance framework that have taken place over the summer months.
The summer period is what is known as the ‘national Semester’ – the time when member states integrate the guidance offered in the Country Specific Recommendations (CSRs) into their national fiscal policy and budgets. For the European institutions, it is a relatively quiet period, as the (...)
On 15 July 2015 EPHA and Wemos hosted an event in the Members’ Salon at the European Parliament to highlight the issue of added therapeutic value (ATV) in medicines.
Several studies carried out at EU member state level indicate that the majority of medicines authorised for use have little-to-no ATV in comparison with existing treatments. This means that public money is being spent on new, costly medicines which have limited ATV, whilst also using up resources which might otherwise be (...)
Supplying poor and developing countries with medicines at sustainable, reduced prices is one of the most important tools in the fight against major diseases, especially the “Big Three”, namely HIV, TB and malaria. After more than a decade since the Council Regulation (EC) 953/2003 came into force, to avoid trade diversion into the European Union of certain key medicines, stakeholders came together to discuss the overall impact of the Regulation at a workshop on 15 July 2015, (...)
Public health is not just about human diseases, healthcare services or cross-border pandemics. Most of all, health is about people. Giving wider attention to the individual also fits perfectly with the European 2020 vision of ’smart, inclusive and sustainable’ growth for a healthier EU, as highlighted at a recent meeting on ’health literacy in Europe’ organised by STOA - European Parliament Science and Technology Options Assessment - on 1 July 2015.
People are used (...)
The most recent meeting of the MEP Interest Group on Complementary and Alternative Medicine (CAM) took place on 1 July 2015 at the European Parliament. Hosted by MEP Sirpa Pietikaeinen (EPP, Finland), it focused on the gap in availability of CAM products and treatments in many EU Member States.
To kick off the meeting, MEP Sirpa Pietikaeinen recalled that a large number of people in Europe - currently estimated to be about 50% of the population - have already used CAM products, which (...)
In June 2015, Germany passed new legislation on disease prevention and health promotion which is unique in the sense that it will create a broad coalition of national health actors on prevention. The latter is not only supposed to create long-term economic benefits for the health system (’return on prevention’) but will bring concrete benefits to a wide range of individuals.
Crucially, the new prevention law (Praeventionsgesetz) will allow individuals to get reimbursed through (...)
The objective of the European Public Health Community is to protect and promote public health by ensuring policy and regulatory space for governments and the EU by incorporating flexibility: Improved well-being of people should be the primary objective of EU policies, and EU trade policy is regarded as a tool to achieve a number of public interest objectives, including, protection of public health, the environment and consumer interests.
- EPHA Position How to include Public Health into (...)
To intensify the dialogue among civil society organisations, TTIP negotiators and political decision makers, Demeter International, in cooperation with the European Public Health Alliance (EPHA) organised the European policy conference “TTIP - Increased Trade for Better Living?" The event took place on 15-16 June under the umbrella of the Agricultural and Rural Convention (ARC 2020) and was hosted by the European and Economic Social Committee (EESC) in Brussels. The conference aims (...)
Brussels, 8th July – Today, the European Parliament adopted its Initiative report with recommendations to the European Commission on the negotiations for the Transatlantic Trade and Investment Partnership (TTIP). EPHA and EHN welcome the report as it includes vital safeguards for public health, and sends a clear signal that the controversial Investor-to-State Dispute Settlement system (ISDS) must be reformed.
It is essential that EU trade agreements do not limit the ability of (...)
The June Uppsala Health Summit (UHS), ‘A World Without Antibiotics’ expanded the discussion about antimicrobial resistance (AMR) at European and national level by examining this critical health threat from different angles. Among the key themes discussed were access to antibiotics and to improved diagnostics, the environmental dimension of AMR, collaborative research & innovation, and economic models allowing pharma companies to balance profits and investments for the public (...)
Access to Medicines
Pharmaceuticals and Medicines
Vaccines and Immunization
complementary and alternative medicine
Antimicrobial Resistance (AMR)